FA
RDY icon

Forefront Analytics’s Dr. Reddy's Laboratories RDY Stock Holding History

Forefront Analytics’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,370
Closed -$27.2K – 125
2020
Q1 		$27.2K Buy
+3,370
New +$28.1K 0.02% 78

Other funds holding RDY

Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AG
Aperio Group Sausalito, California $33.8B AUM 31.46% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Forefront Analytics's RDY Position: Q2 2020 in Review

Forefront Analytics sold out of Dr. Reddy's Laboratories (RDY) in Q2 2020, closing a stake of 3,370 shares — an estimated $27.2K sold.

Forefront Analytics first reported a position in RDY in Q1 2020 and held it in 1 quarter. The position peaked at $27.2K in Q1 2020. 169 funds tracked by Wall St. Rank hold RDY as of Q2 2020.

  • Forefront Analytics reported no remaining Dr. Reddy's Laboratories position as of Q2 2020 after selling out during the quarter.
  • Forefront Analytics sold 3,370 Dr. Reddy's Laboratories shares in Q2 2020, an estimated $27.2K.
  • Forefront Analytics first reported a position in Dr. Reddy's Laboratories in Q1 2020 and held it in 1 quarter.
  • Forefront Analytics's Dr. Reddy's Laboratories position peaked at $27.2K in Q1 2020.
  • 169 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q2 2020.

Based on Forefront Analytics's 13F filing for Q2 2020, filed 10 Aug 2020.